What's Happening?
Aprés, a new company, has launched chewable digestive enzyme mints designed to help individuals with FODMAP sensitivity. The product, developed by Jesse Pagliuca after experiencing his own digestive issues post-COVID-19, aims to provide a convenient and
discreet solution for managing symptoms related to consuming high-FODMAP foods. The mints contain eight enzymes, with a specific focus on breaking down lactose, galacto-oligosaccharides (GOS), and fructans, which are common FODMAP triggers found in foods like dairy, beans, garlic, and onions. Aprés emphasizes using clinically tested doses of enzymes, such as 9,000 ALU of lactase and 1,600 GalU of alpha-galactosidase, and 400 INU of OPTIZIOME® Fructanase, to ensure efficacy. The company also highlights transparency by listing the activity level of each ingredient and sourcing enzymes from BIO-CAT, a reputable manufacturer.
Why It's Important?
This product launch is significant for the millions of Americans who suffer from digestive issues, particularly those with FODMAP sensitivities or Irritable Bowel Syndrome (IBS). The low-FODMAP diet is a common strategy for managing IBS symptoms, but it can be restrictive and challenging to maintain, especially when dining out. Aprés offers a potential tool to allow individuals to reintroduce a wider variety of foods into their diet with reduced discomfort. By providing a discreet, chewable format, the product addresses a common pain point for users of digestive aids, who often find existing options stigmatizing or inconvenient. The emphasis on clinically tested doses and transparency in ingredient labeling could build trust among consumers seeking effective solutions for their digestive health.
What's Next?
Aprés is currently in the process of pursuing FODMAP certification for its product, which, if successful, would further validate its claims and potentially increase consumer confidence. The company also plans to conduct clinical trials on the complete formula to gather more data on its efficacy in individuals with IBS or documented food intolerances. Furthermore, Aprés is assembling an advisory board of registered dietitians, gastroenterologists, and other experts to guide product development and communication, suggesting a commitment to scientific rigor and professional endorsement. Future product offerings may also emerge based on customer feedback and expert advice, expanding the range of solutions for digestive health.
Beyond the Headlines
The development of Aprés reflects a growing trend in the health and wellness industry towards personalized and convenient solutions for chronic conditions. The founder's personal experience with digestive issues highlights the increasing demand for products that not only address symptoms but also integrate seamlessly into daily life without causing social discomfort. The focus on transparency in enzyme activity and sourcing also points to a broader consumer desire for clear, evidence-based information about supplements. This product could contribute to a shift in how digestive health is managed, moving beyond strict dietary avoidance to a more flexible approach supported by targeted enzyme supplementation, potentially improving the quality of life for many individuals with food sensitivities.













